Aveo Pharmaceuticals Inc
NASDAQ:AVEO
Aveo Pharmaceuticals Inc
Cash Equivalents
Aveo Pharmaceuticals Inc
Cash Equivalents Peer Comparison
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Aveo Pharmaceuticals Inc
NASDAQ:AVEO
|
Cash Equivalents
$77.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash Equivalents
$18.1B
|
CAGR 3-Years
23%
|
CAGR 5-Years
30%
|
CAGR 10-Years
8%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Equivalents
$4.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Equivalents
$9.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Equivalents
$9.2B
|
CAGR 3-Years
13%
|
CAGR 5-Years
26%
|
CAGR 10-Years
36%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Equivalents
$2.6B
|
CAGR 3-Years
22%
|
CAGR 5-Years
9%
|
CAGR 10-Years
19%
|
See Also
What is Aveo Pharmaceuticals Inc's Cash Equivalents?
Cash Equivalents
77.4m
USD
Based on the financial report for Sep 30, 2022, Aveo Pharmaceuticals Inc's Cash Equivalents amounts to 77.4m USD.
What is Aveo Pharmaceuticals Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
36%
Over the last year, the Cash Equivalents growth was 12%. The average annual Cash Equivalents growth rates for Aveo Pharmaceuticals Inc have been 10% over the past three years , 36% over the past five years .